This Leqembi market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth observed during the historic period can be attributed to factors such as an increase in the elderly population, higher funding allocations by governments and organizations for neurodegenerative disease research, improvements in reimbursement and coverage, ongoing clinical trial results, and a rise in healthcare spending.
Market growth during the forecast period is driven by factors such as increased research and development investments, greater awareness of early Alzheimer's diagnosis, the growing global prevalence of Alzheimer's disease, a higher demand for treatments for neurodegenerative disorders, and a stronger focus on reducing amyloid plaques. Key trends expected in the forecast period include advancements in neuroscience research, the rise of digital health technologies, improvements in Alzheimer's treatments, a shift towards personalized medicine, and the development of disease-modifying therapies.
The rising prevalence of Alzheimer's disease is expected to drive the growth of the leqembi market. Alzheimer's is a degenerative brain disorder that progressively impacts memory, cognition, and behavior, severely affecting daily life. The development of Alzheimer's disease is influenced by a combination of genetic, lifestyle, and environmental factors. Leqembi works by reducing beta-amyloid plaques in the brain, which helps slow cognitive decline in the early stages of Alzheimer's by targeting these plaques and preserving memory and cognitive functions. For example, in September 2024, the European Brain Council, a Belgium-based international health organization, reported that approximately 7 million people in Europe are living with Alzheimer's, with this number expected to double to 14 million by 2030 due to the aging population, making it a significant global public health challenge. As a result, the increasing prevalence of Alzheimer's disease is contributing to the expansion of the leqembi market.
The leqembi market is being driven by advancements in intravenous (IV) maintenance dosing formulations for Alzheimer's treatment. This approach involves delivering a consistent or recurring dose of medication directly into the bloodstream, ensuring sustained therapeutic levels over time. For instance, in June 2024, Eisai Co., Ltd., a Japan-based pharmaceutical company, and Biogen Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had accepted a supplemental biologics license application (sBLA) for a monthly IV maintenance dosing regimen of LEQEMBI. This treatment targets toxic amyloid proteins, particularly protofibrils, which are believed to play a role in cognitive decline in Alzheimer's disease. LEQEMBI has demonstrated clinical and biomarker benefits, potentially extending treatment efficacy, reducing neuronal damage, and improving long-term patient outcomes.
In November 2024, Biogen Inc. and Eisai Co., Ltd. formed a partnership to develop and commercialize treatments for Alzheimer's disease, with a focus on Leqembi (lecanemab) for patients in the early stages of the disease. Eisai Co. Ltd. is the pharmaceutical company responsible for manufacturing leqembi.
The key company operating in the leqembi market is Eisai Co. Ltd.
North America was the largest region in the leqembi market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leqembi report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the leqembi market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Leqembi is a prescription medication used to treat Alzheimer's disease. This drug is specifically designed to address the progressive neurodegenerative disorder, which leads to memory loss, cognitive decline, and difficulties in daily functioning. Leqembi works by targeting the underlying cause of Alzheimer's, reducing amyloid-beta plaques in the brain that are thought to contribute to the disease’s progression.
The primary types of leqembi formulations are injectable forms, including intravenous injections and ready-to-use solutions. The intravenous injectable formulation delivers the medication directly into the bloodstream for rapid absorption and precise dosing, making it ideal for patients with advanced stages of the disease or those requiring consistent medication levels. It is used for various indications, including the treatment of Alzheimer’s disease, management of mild cognitive impairment, and other conditions. It is suitable for adult, geriatric, and early-stage Alzheimer's patients. Leqembi is distributed through direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies, and is utilized by hospitals, neurology clinics, memory care facilities, and home healthcare providers.
The leqembi market research report is one of a series of new reports that provides leqembi market statistics, including the leqembi industry global market size, regional shares, competitors with the leqembi market share, detailed leqembi market segments, market trends, and opportunities, and any further data you may need to thrive in the leqembi industry. This leqembi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The leqembi market consists of sales of oral tablets or capsules, subcutaneous injections, and transdermal patches. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth observed during the historic period can be attributed to factors such as an increase in the elderly population, higher funding allocations by governments and organizations for neurodegenerative disease research, improvements in reimbursement and coverage, ongoing clinical trial results, and a rise in healthcare spending.
Market growth during the forecast period is driven by factors such as increased research and development investments, greater awareness of early Alzheimer's diagnosis, the growing global prevalence of Alzheimer's disease, a higher demand for treatments for neurodegenerative disorders, and a stronger focus on reducing amyloid plaques. Key trends expected in the forecast period include advancements in neuroscience research, the rise of digital health technologies, improvements in Alzheimer's treatments, a shift towards personalized medicine, and the development of disease-modifying therapies.
The rising prevalence of Alzheimer's disease is expected to drive the growth of the leqembi market. Alzheimer's is a degenerative brain disorder that progressively impacts memory, cognition, and behavior, severely affecting daily life. The development of Alzheimer's disease is influenced by a combination of genetic, lifestyle, and environmental factors. Leqembi works by reducing beta-amyloid plaques in the brain, which helps slow cognitive decline in the early stages of Alzheimer's by targeting these plaques and preserving memory and cognitive functions. For example, in September 2024, the European Brain Council, a Belgium-based international health organization, reported that approximately 7 million people in Europe are living with Alzheimer's, with this number expected to double to 14 million by 2030 due to the aging population, making it a significant global public health challenge. As a result, the increasing prevalence of Alzheimer's disease is contributing to the expansion of the leqembi market.
The leqembi market is being driven by advancements in intravenous (IV) maintenance dosing formulations for Alzheimer's treatment. This approach involves delivering a consistent or recurring dose of medication directly into the bloodstream, ensuring sustained therapeutic levels over time. For instance, in June 2024, Eisai Co., Ltd., a Japan-based pharmaceutical company, and Biogen Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had accepted a supplemental biologics license application (sBLA) for a monthly IV maintenance dosing regimen of LEQEMBI. This treatment targets toxic amyloid proteins, particularly protofibrils, which are believed to play a role in cognitive decline in Alzheimer's disease. LEQEMBI has demonstrated clinical and biomarker benefits, potentially extending treatment efficacy, reducing neuronal damage, and improving long-term patient outcomes.
In November 2024, Biogen Inc. and Eisai Co., Ltd. formed a partnership to develop and commercialize treatments for Alzheimer's disease, with a focus on Leqembi (lecanemab) for patients in the early stages of the disease. Eisai Co. Ltd. is the pharmaceutical company responsible for manufacturing leqembi.
The key company operating in the leqembi market is Eisai Co. Ltd.
North America was the largest region in the leqembi market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leqembi report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the leqembi market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Leqembi is a prescription medication used to treat Alzheimer's disease. This drug is specifically designed to address the progressive neurodegenerative disorder, which leads to memory loss, cognitive decline, and difficulties in daily functioning. Leqembi works by targeting the underlying cause of Alzheimer's, reducing amyloid-beta plaques in the brain that are thought to contribute to the disease’s progression.
The primary types of leqembi formulations are injectable forms, including intravenous injections and ready-to-use solutions. The intravenous injectable formulation delivers the medication directly into the bloodstream for rapid absorption and precise dosing, making it ideal for patients with advanced stages of the disease or those requiring consistent medication levels. It is used for various indications, including the treatment of Alzheimer’s disease, management of mild cognitive impairment, and other conditions. It is suitable for adult, geriatric, and early-stage Alzheimer's patients. Leqembi is distributed through direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies, and is utilized by hospitals, neurology clinics, memory care facilities, and home healthcare providers.
The leqembi market research report is one of a series of new reports that provides leqembi market statistics, including the leqembi industry global market size, regional shares, competitors with the leqembi market share, detailed leqembi market segments, market trends, and opportunities, and any further data you may need to thrive in the leqembi industry. This leqembi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The leqembi market consists of sales of oral tablets or capsules, subcutaneous injections, and transdermal patches. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Leqembi Market Characteristics4. Leqembi Market Trends and Strategies5. Leqembi Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Leqembi Pricing Analysis & Forecasts30. Global Leqembi Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Leqembi Market32. Recent Developments in the Leqembi Market
3. Leqembi Market Biologic Drug Characteristics
6. Global Leqembi Growth Analysis and Strategic Analysis Framework
8. Leqembi Market Segmentation
9. Global Leqembi Epidemiology of Clinical Indications
10. Leqembi Market Regional and Country Analysis
11. Asia-Pacific Leqembi Market
12. China Leqembi Market
13. India Leqembi Market
14. Japan Leqembi Market
15. Australia Leqembi Market
16. South Korea Leqembi Market
17. Western Europe Leqembi Market
18. UK Leqembi Market
19. Germany Leqembi Market
20. France Leqembi Market
21. Eastern Europe Leqembi Market
22. North America Leqembi Market
23. USA Leqembi Market
24. Canada Leqembi Market
25. South America Leqembi Market
26. Middle East Leqembi Market
27. Africa Leqembi Market
28. Leqembi Market Competitive Landscape and Company Profiles
29. Global Leqembi Market Pipeline Analysis
33. Leqembi Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Leqembi Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on leqembi market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for leqembi? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The leqembi market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Formulation: Injectable Formulation (Intravenous); Ready-to-Use Solutions2) by Indication: Treatment of Alzheimer’s Disease; Management of Mild Cognitive Impairment; Other Neurodegenerative Disorders
3) by Patient Demographics: Adult Patients; Geriatric Patients; Patients With Early-Stage Alzheimer’s Disease
3) by Distribution Channel: Direct Sales; Wholesalers and Distributors; Retail Pharmacies; Online Pharmacies
5) by End-User: Hospitals; Neurology Clinics; Memory Care Facilities; Home Healthcare Providers
Key Companies Mentioned: Eisai Co. Ltd.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Eisai Co. Ltd.
